MX367461B - Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa. - Google Patents

Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa.

Info

Publication number
MX367461B
MX367461B MX2015009924A MX2015009924A MX367461B MX 367461 B MX367461 B MX 367461B MX 2015009924 A MX2015009924 A MX 2015009924A MX 2015009924 A MX2015009924 A MX 2015009924A MX 367461 B MX367461 B MX 367461B
Authority
MX
Mexico
Prior art keywords
carboximethylcellulose
sodium hyaluronate
including sodium
artificial tears
tears including
Prior art date
Application number
MX2015009924A
Other languages
English (en)
Other versions
MX2015009924A (es
Inventor
G Vehige Joseph
A Simmons Peter
M Blanda Wendy
A Marsh David
J Beard Bereth
Haixia Liu
S Matsumoto Steven
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2015009924A publication Critical patent/MX2015009924A/es
Publication of MX367461B publication Critical patent/MX367461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se refiere a formulaciones y métodos de uso para formulaciones de gotas oftálmicas que comprenden carboximetilcelulosa (CMC) y ácido hialurónico (HA) con una mejora de la distribución sobre la córnea durante el parpadeo.
MX2015009924A 2013-02-01 2014-02-03 Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa. MX367461B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759710P 2013-02-01 2013-02-01
US201361785857P 2013-03-14 2013-03-14
PCT/US2014/014505 WO2014121232A1 (en) 2013-02-01 2014-02-03 Artificial tears comprising sodium hyaluronate and carboxymethylcellulose

Publications (2)

Publication Number Publication Date
MX2015009924A MX2015009924A (es) 2015-09-25
MX367461B true MX367461B (es) 2019-08-21

Family

ID=50113045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009924A MX367461B (es) 2013-02-01 2014-02-03 Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa.

Country Status (23)

Country Link
US (5) US20140221309A1 (es)
EP (2) EP3517100B1 (es)
JP (2) JP6527468B2 (es)
KR (1) KR102227202B1 (es)
CN (2) CN104981234A (es)
AU (2) AU2014212025A1 (es)
BR (1) BR112015018414B1 (es)
CA (1) CA2898217C (es)
CY (1) CY1124054T1 (es)
DK (2) DK3517100T3 (es)
ES (2) ES2741141T3 (es)
HR (1) HRP20191382T1 (es)
HU (2) HUE044555T2 (es)
LT (1) LT2950783T (es)
MX (1) MX367461B (es)
PL (2) PL3517100T3 (es)
PT (2) PT2950783T (es)
RS (1) RS59271B1 (es)
RU (1) RU2687275C2 (es)
SA (1) SA517381008B1 (es)
SI (2) SI2950783T1 (es)
WO (1) WO2014121232A1 (es)
ZA (1) ZA201505026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170014339A1 (en) * 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
WO2017075019A1 (en) * 2015-10-28 2017-05-04 Welch David B Eye drops
ES2621877B1 (es) * 2016-01-04 2018-05-04 Agencia Pública Empresarial Sanitaria Hospital De Poniente Solución para resección endoscópica
US10632202B2 (en) * 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
HRP20251646T1 (hr) * 2017-06-09 2026-02-13 Omnivision Gmbh Pripravak za liječenje suhog oka
EP3781175A1 (en) * 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12611460B2 (en) 2018-09-20 2026-04-28 The Hong Kong University Of Science And Technology Eyedrop compositions
KR102051356B1 (ko) * 2019-01-03 2019-12-03 (주)휴온스 고농도의 히알루론산 또는 그의 염을 함유하는 점안 조성물
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
WO2022189548A1 (en) * 2021-03-10 2022-09-15 Bausch + Lomb Ireland Limited Contact lens treating solution
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6271216B1 (en) * 1989-07-24 2001-08-07 Allergan Stable solution of hyaluronate in a balanced salt medium
EP1174463A4 (en) * 1999-02-19 2008-04-16 Denki Kagaku Kogyo Kk GEL FROM HYALURONIC ACID, METHOD FOR THE PRODUCTION THEREOF, AND THIS CONTAINING MEDICINE MATERIAL
EP1162984A2 (en) 1999-03-15 2001-12-19 Trustees Of Boston University Use of cross linked polysaccharides for the inhibition of angiogenesis
KR20020050240A (ko) * 1999-11-09 2002-06-26 구이도 콜러, 스테판 바슬러 하이드록시에이코사테트라에노에이트 염, 조성물 및 안구건조증 치료에서의 사용 방법
CA2393354A1 (en) * 1999-12-17 2001-06-21 Timothy J. Butler Surgical prosthesis
CN1485395A (zh) * 2002-09-25 2004-03-31 宋海涛 一种环保型“冷热液”
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
JP2006052160A (ja) * 2004-08-10 2006-02-23 Rohto Pharmaceut Co Ltd ドライアイ治療用眼科組成物
JP2006143590A (ja) * 2004-10-21 2006-06-08 Rohto Pharmaceut Co Ltd 粘膜適用組成物
JP2008519846A (ja) * 2004-11-09 2008-06-12 アドバンスト メディカル オプティクス， インコーポレーテッド 眼科用溶液
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
AR062046A1 (es) * 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
AR063561A1 (es) * 2006-11-06 2009-02-04 Novartis Ag Dispositivos oculares y metodos para fabricar y utilizar los mismos
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
KR100938500B1 (ko) * 2008-06-24 2010-01-28 주식회사 디에이치피코리아 안과질환 예방 및 치료용 점안제 조성물
KR100827400B1 (ko) * 2008-06-24 2008-05-06 김정춘 파이프 연결구를 갖는 수도계량기 및 그 제조방법
US20100086512A1 (en) 2008-10-02 2010-04-08 Rolf Schaefer Mucomimetic compositions and uses therefore
WO2010047927A1 (en) * 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
AU2010339993A1 (en) * 2009-12-15 2012-07-26 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
CN101785852A (zh) * 2010-01-21 2010-07-28 孙杰 一种真皮层微量介入美容抗衰除皱制剂与方法
CN101884602A (zh) * 2010-03-03 2010-11-17 孙杰 一种皮肤美容修复抗衰除皱的化妆品制剂

Also Published As

Publication number Publication date
AU2014212025A1 (en) 2015-08-20
KR20150113156A (ko) 2015-10-07
RS59271B1 (sr) 2019-10-31
BR112015018414B1 (pt) 2022-11-08
JP2016507529A (ja) 2016-03-10
US20260069627A1 (en) 2026-03-12
CN104981234A (zh) 2015-10-14
HK1218517A1 (en) 2017-02-24
US20160235780A1 (en) 2016-08-18
EP2950783B1 (en) 2019-05-15
SI2950783T1 (sl) 2019-10-30
BR112015018414A2 (pt) 2017-07-18
EP2950783A1 (en) 2015-12-09
KR102227202B1 (ko) 2021-03-12
US20220096531A1 (en) 2022-03-31
EP3517100A1 (en) 2019-07-31
AU2018260857A1 (en) 2018-11-22
HUE044555T2 (hu) 2019-11-28
MX2015009924A (es) 2015-09-25
WO2014121232A1 (en) 2014-08-07
JP6876079B2 (ja) 2021-05-26
PT3517100T (pt) 2020-12-15
US20140221309A1 (en) 2014-08-07
RU2687275C2 (ru) 2019-05-13
PL2950783T3 (pl) 2019-11-29
CN111419794A (zh) 2020-07-17
SA517381008B1 (ar) 2019-08-31
AU2018260857B2 (en) 2020-05-07
CA2898217C (en) 2021-08-31
DK2950783T3 (da) 2019-07-22
PL3517100T3 (pl) 2021-04-19
CA2898217A1 (en) 2014-08-07
CY1124054T1 (el) 2022-03-24
DK3517100T3 (da) 2020-12-14
ES2841434T3 (es) 2021-07-08
ES2741141T3 (es) 2020-02-10
LT2950783T (lt) 2019-10-25
JP2019112411A (ja) 2019-07-11
US20240285673A1 (en) 2024-08-29
EP3517100B1 (en) 2020-09-09
RU2015132974A (ru) 2017-03-06
SI3517100T1 (sl) 2021-02-26
JP6527468B2 (ja) 2019-06-05
HUE052793T2 (hu) 2021-05-28
HRP20191382T1 (hr) 2019-11-15
ZA201505026B (en) 2016-07-27
PT2950783T (pt) 2019-08-21

Similar Documents

Publication Publication Date Title
CY1124054T1 (el) Τεχνητα δακρυα που περιεχουν υαλουρονικο νατριο και καρβοξυμεθυλοκυτταρινη
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
BR112017011327A2 (pt) sistema e método de detecção de umidificação e sistema de gerenciamento de incontinência
PH12017500922A1 (en) Stabilized omega-3 ophthalmic compositions
BR112014027582A2 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
EP2911671A4 (en) PYRAZOLOPYRIDAZINE AND METHOD FOR THE TREATMENT OF DEGENERATIVE NETWORK DISEASE AND HEARING LOSS WITH USHER SYNDROME
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
BR112015028325A2 (pt) processo para fabricar lítio carboximetil celulose
AR083962A1 (es) Un producto a base de te
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo
BR112014020424A2 (pt) ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata
CO7141425A2 (es) Composiciones oftálmicas con retención y protección de desecación mejoradas
TWD159196S (zh) 眼內鏡片植入具
TWD159197S (zh) 眼內鏡片植入具
CL2010000695A1 (es) Composicion oftalmica acuosa que comprende una ciclosporina,glicerina y agua, donde la composicion contiene menos de 0,3% de cloruro de sodio y menos de 0,04% de metabisulfito de sodio; y uso para tratar una condicion ocular.
TWD176447S (zh) 護目鏡
PL412941A1 (pl) Preparat na zmarszczki
UA36913U (uk) Очна мазь для лікування запальних та дистрофічних захворювань переднього відтинку ока
BR112016002349A2 (pt) composição de vacina substancialmente estável, processo para fabricar uma composição de vacina substancialmente estável, métodos para tratar um paciente e para induzir uma resposta imunogênica, uso de monocloridrato de arginina, e, recipiente

Legal Events

Date Code Title Description
FG Grant or registration